On 3rd September 2020, the Extraordinary General Meeting of shareholders of Helix Immuno-Oncology S.A. (“Company“) adopted a resolution concerning:

  1. An increase in the initial capital of the Company by the amount of 558,518.50 PLN through emission of 5,585,185 common registered shares, each with the nominal value of 0.10 PLN (10/100 PLN), marked as series C, while depriving hitherto shareholders of the stock right in whole and the right to change the charter of the Company.
  2. Adoption of a consolidated text of the charter of the Company.

As a consequence of adoption of the above-mentioned resolutions by the Extraordinary General Meeting of shareholders of the Company, 5,585,185 common registered shares, each with the nominal value of 0.10 PLN, marked as series C, were acquired by the ACRX INVESTMENT LIMITED company with the registered office in Nicosia (Cyprus) through private placing. Series C shares were acquired in return for cash contribution. The issue price of series C shares is 1.35 PLN per share.